Laser Therapy in Brampton

Therapeutic laser - more precisely termed photobiomodulation therapy (PBMT), formerly called Low Level Laser Therapy (LLLT) - is the clinical application of specific wavelengths of light (typically in the red 630-700 nm and near-infrared 780-1100 nm ranges) at non-thermal doses to modulate cellular physiology. The primary molecular target is cytochrome c oxidase in the mitochondrial electron transport chain (Karu 2003, Hamblin 2017): photon absorption displaces inhibitory nitric oxide from the enzyme, increases ATP production, modulates reactive oxygen species signaling, elevates nitric oxide release (local vasodilation and improved microcirculation), and triggers transcription of anti-inflammatory and tissue-repair genes. This mechanism is well-characterized in the peer-reviewed basic-science literature and is endorsed by the World Association for Photobiomodulation Therapy (WALT), which publishes dose and protocol guidelines organized by anatomical target and laser class.

Our clinic uses Class IV therapeutic laser systems. Class IV lasers deliver high output power (commonly 5-25 watts), enabling deeper tissue penetration (up to 5-7 cm with appropriate wavelength combinations) and shorter treatment times (typically 5-15 minutes per region) compared to the older, lower-power Class IIIb "cold laser" devices. The higher total energy delivered in a short session allows dosing that actually meets the WALT-recommended thresholds for clinical effect - a common reason older LLLT trials produced inconsistent results was under-dosing. Class IV laser is not surgical laser - it is non-ablative, non-thermal at therapeutic settings, and produces no tissue damage at the skin surface.

The evidence base for photobiomodulation has strengthened substantially in the last decade. Supporting data include: Chow 2009 Lancet systematic review (16 RCTs, n=820) showing moderate-quality evidence for PBMT in chronic neck pain; Bjordal 2008 meta-analysis supporting PBMT for lateral epicondylitis; Huang 2015 meta-analysis for knee osteoarthritis; Jang 2014 Cochrane update for low back pain; Stausholm 2019 systematic review/meta-analysis in BMJ Open (22 RCTs, n=1,063) demonstrating clinically relevant pain reduction in knee OA when WALT dose recommendations are met; and Cochrane 2017 (Lam) for carpal tunnel syndrome showing symptom and function improvement. The common theme: PBMT works when dosed properly per the anatomy targeted - too little energy yields no effect, too much may slow healing (biphasic dose response). Our clinicians calculate dose based on wavelength, power, pulse characteristics, treatment area, and patient-specific factors (skin tone, tissue depth, BMI).

• Chronic tendinopathy - rotator cuff, lateral epicondylitis (tennis elbow), medial epicondylitis (golfer's elbow), patellar tendinopathy (jumper's knee), Achilles tendinopathy, plantar fasciitis. Bjordal 2008 meta-analysis supports PBMT as an adjunct with active eccentric/heavy-slow-resistance loading.
• Knee osteoarthritis - moderate-quality evidence for pain reduction (Stausholm 2019, Huang 2015) when WALT dose met; adjunct to GLA:D and strengthening programs.
• Chronic neck pain - Chow 2009 Lancet review supports PBMT as part of combined conservative care.
• Chronic low back pain - Jang 2014 Cochrane update, adjunct to exercise-based rehabilitation.
• Carpal tunnel syndrome - Lam 2017 Cochrane: symptom and function improvement; avoids surgery in mild-to-moderate cases.
• Peripheral neuropathy - diabetic and chemotherapy-induced; emerging evidence supports PBMT for sensory symptom reduction.
• Myofascial pain and trigger points - combined with dry needling or manual release for potent synergistic effect.
• Post-surgical wound healing and scar management - accelerates wound closure, reduces scar hypertrophy when started early.
• Bursitis - trochanteric, subacromial, olecranon, pes anserine bursitis.
• Fibromyalgia tender-point pain - moderate-quality evidence for short-term pain reduction.
• Temporomandibular joint (TMJ) dysfunction - pain and functional improvement as adjunct to manual therapy.
• Lymphedema - adjunct to manual lymphatic drainage.
• Herpes zoster (shingles) neuralgia - emerging evidence for post-herpetic pain modulation.

Session structure (5-15 minutes): the treatment area is cleaned. Both you and the therapist wear appropriate laser safety glasses matched to the wavelength - this is mandatory because near-infrared light can damage the retina even though the light is invisible. The laser handpiece is applied directly to the skin over the target tissue (through a sterile applicator sleeve or acoustic coupling gel) and moved in a slow systematic pattern to cover the treatment region. You may feel a gentle warmth on the skin but the sensation is never painful. Treatment doses are calculated based on condition, anatomy, and WALT guideline recommendations - typically 4-10 J/cm^2 per target region for superficial tissue and 10-30 J/cm^2 for deeper structures.

Typical course: 6-12 sessions, 2-3 times per week, with clinical reassessment at sessions 4, 8, and 12. Response is usually evident by session 4-6; if no improvement is noted by session 6, we re-evaluate the diagnosis and treatment plan rather than continue indefinitely. Acute conditions typically resolve faster than chronic conditions.

Safety profile: PBMT is exceptionally well-tolerated with no known significant adverse effects when dosed and applied per guideline. Rare minor effects include transient treatment-site warmth or mild redness for hours after treatment.

Contraindications: absolute - direct irradiation of the eye, pregnancy (avoid direct uterine/abdominal irradiation), active malignancy within the treatment area (photobiomodulation can theoretically accelerate cellular proliferation), active hemorrhage, photosensitive medications (e.g., certain tetracyclines, St John's Wort, retinoids - check all current medications), acutely infected or febrile patient. Relative - open growth plates in skeletally immature patients (use with caution at reduced dose), implanted electronic devices directly under the treatment site (generally safe but we discuss with the patient), tattoos (higher skin absorption of heat - reduce dose), very dark skin (higher surface absorption - may need wavelength or dose adjustment).

Integration with active rehabilitation: PBMT is most effective as an adjunct to active rehabilitation - loading the tendon, strengthening the quadriceps, and correcting the biomechanics that caused the problem in the first place. We do not offer laser as a stand-alone "feel better without doing the work" modality. Every laser session is paired with or embedded within a physiotherapy visit that includes manual therapy, exercise prescription, and education.

Coverage: laser therapy is delivered and billed under the physiotherapy benefit on your extended health plan. Direct billing to all major Canadian insurers. WSIB and MVA-SABS covered where the condition relates to a workplace injury or motor vehicle collision. No doctor's referral required in Ontario.